Biotech patent owners may be missing a trick by ignoring the ITC
The rise of biosimilar disputes, and the growing importance of life sciences innovations outside human therapeutics, could see an upswing in Section 337 actions
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.